These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20146086)

  • 1. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.
    Clarke JL; Pao W; Wu N; Miller VA; Lassman AB
    J Neurooncol; 2010 Sep; 99(2):283-6. PubMed ID: 20146086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
    Katayama T; Shimizu J; Suda K; Onozato R; Fukui T; Ito S; Hatooka S; Sueda T; Hida T; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Nov; 4(11):1415-9. PubMed ID: 19692934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
    Grommes C; Oxnard GR; Kris MG; Miller VA; Pao W; Holodny AI; Clarke JL; Lassman AB
    Neuro Oncol; 2011 Dec; 13(12):1364-9. PubMed ID: 21865399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
    Togashi Y; Masago K; Masuda S; Mizuno T; Fukudo M; Ikemi Y; Sakamori Y; Nagai H; Kim YH; Katsura T; Mishima M
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):399-405. PubMed ID: 22806307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
    Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
    J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
    Kawamura T; Hata A; Takeshita J; Fujita S; Hayashi M; Tomii K; Katakami N
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1261-6. PubMed ID: 25921002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
    Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
    Lee Y; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
    J Neurooncol; 2013 Oct; 115(1):95-101. PubMed ID: 23832498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma.
    Wagner M; Besse B; Balleyguier C; Soria JC
    J Thorac Oncol; 2008 Jun; 3(6):677-9. PubMed ID: 18520813
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
    Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
    Fukuhara T; Saijo Y; Sakakibara T; Inoue A; Morikawa N; Kanamori M; Nakashima I; Nukiwa T
    Tohoku J Exp Med; 2008 Apr; 214(4):359-63. PubMed ID: 18441512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
    Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
    Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
    Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.